Topics: $IOVA would be somewhere between...; Costco Wholesale (COST) Q3 2022...; T-Mobile (TMUS) Up 0.3% Since Last... and many other

[Limex] Dear {NAME}, Some topics you might have missed. --------------------------------------------------------------- [$IOVA would be somewhere between $2.12 and $6.13 by 27 May 2022.]( … [Read more]( Actionable news --------------------------------------------------------------- [Costco Wholesale (COST) Q3 2022 Earnings Call Transcript]( Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good day, and thank you for standing by. Welcome to the … [Read more]( Actionable news --------------------------------------------------------------- [T-Mobile (TMUS) Up 0.3% Since Last Earnings Report: Can It Continue?]( A month has gone by since the last earnings report for T-Mobile (TMUS). Shares have added about 0.3% in that time frame, outperforming the S&P … [Read more]( Actionable news --------------------------------------------------------------- [Why Novavax Is Up More Than 18% Today]( What happened Shares of drugmaker Novavax (NASDAQ: NVAX) are up to the tune of 18.9% as of 2:11 p.m. ET Friday, according to data from S&P Global … [Read more]( Actionable news --------------------------------------------------------------- [Wave of Dismal Q1 Earnings Drags Retail ETFs Down]( The overall earnings picture for the retail sector in Q1 earnings has been disappointing, raising questions about the health of the consumer in the … [Read more]( Actionable news --------------------------------------------------------------- [Pfizer (PFE) Gets Fast Track Designation for NASH Therapy]( Pfizer PFE recently announced that the FDA has granted Fast Track designation to its investigational combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. The investigational therapy comprises ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi). The designation from the regulatory body facilitates the development and expedites the review of new drugs and vaccines intended to treat or prevent serious conditions and address the unmet medical need. NASH is a serious, progressive form of non-alcoholic fatty liver disease (NAFLD) caused by a buildup of fat in the liver and accompanied by inflammation, liver cell damage, and in some cases, scarring of the liver. The combination under investigation — diacylglycerol O-acyltransferase 2 (DGAT2) and ACC — are two key enzymes that regulate lipid metabolism. Inhibitors of ACC and DGAT2 have demonstrated the ability to lower liver fat in patients with NAFLD. Hence, Pfizer expects the combination to lead to direct improvements in inflammation and fibrosis. Pfizer is currently evaluating the combination in an ongoing mid-stage study. The study is evaluating the impact of treatment on the resolution of NASH or improvement in liver fibrosis and is expected to complete in 2024. The results of this study, which also includes arms investigating ervogastat as monotherapy, will inform a potential phase III development program. Pfizer’s stock is down 8.5% this year so far against an increase of 5.8% for the industry. While the NASH market promises potential with no approved therapies yet, it is challenging. Quite a few players are trying their hand at successfully developing a treatment for the same. Intercept Pharmaceuticals ICPT is evaluating obeticholic acid for NASH. The company, however, suffered a setback when the FDA issued a complete response letter (CRL) for obeticholic acid as it was a frontrunner in receiving a potential approval for the treatment of NASH. ICPT focuses on delivering new interim data analyses from its phase III REGENERATE study in patients with advanced fibrosis due to NASH later this quarter. Intercept is also planning a pre-submission meeting with FDA in June. Another company, Viking Therapeutics VKTX, is developing a candidate, VK2809, for biopsy-confirmed NASH and fibrosis. VK2809 is currently being evaluated in a phase IIb study in patients with NASH. Viking expects to complete enrollment in the second half of 2022. Zacks Rank & Stocks to Consider Pfizer currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the healthcare space is Alkermes ALKS, which has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Loss estimates for ALKS for 2022 have narrowed to 3 cents from a loss of 14 cents in the past 60 days. Alkermes surpassed estimates in all of the trailing four quarters, the average surprise being 350.48%. Just Released: The Biggest Tech IPOs of 2022 For a limited time, Zacks is revealing the most anticipated tech IPOs expected to launch this year. Concerns about Federal interest rates and inflation caused many private companies to stay on the bench- leading to companies with better brand recognition and higher growth rates getting into the game. With the strength of our economy and record amounts of cash flooding into IPOs, you don’t want to miss this opportunity. See the complete list today. >>See Zacks Hottest IPOs Now Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Alkermes plc (ALKS): Free Stock Analysis … [Read more]( Actionable news --------------------------------------------------------------- [Sterling heads for second weekly gain, aided by UK support package]( LONDON, May 27 (Reuters) - Britain's pound headed for a second weekly rise and was close to a one-month high on Friday, helped by a large government … [Read more]( Actionable news --------------------------------------------------------------- [Workday (WDAY) Q1 2023 Earnings Call Transcript]( Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Hello, and welcome to Workday's first-quarter fiscal … [Read more]( Actionable news --------------------------------------------------------------- [JB Hunt (JBHT) Gains But Lags Market: What You Should Know]( JB Hunt (JBHT) closed at $174.86 in the latest trading session, marking a +0.97% move from the prior day. This move lagged the S&P 500's daily gain of 2.47%. At the same time, the Dow added 1.76%, and the tech-heavy Nasdaq gained 0.71%. Coming into today, shares of the trucking and logistics company had lost 0.81% in the past month. In that same time, the Transportation sector lost 2.15%, while the S&P 500 lost 2.59%. JB Hunt will be looking to display strength as it nears its next earnings release. On that day, JB Hunt is projected to report earnings of $2.29 per share, which would represent year-over-year growth of 42.24%. Our most recent consensus estimate is calling for quarterly revenue of $3.54 billion, up 21.83% from the year-ago period. Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $9.30 per share and revenue of $14.33 billion. These totals would mark changes of +30.25% and +17.8%, respectively, from last year. It is also important to note the recent changes to analyst estimates for JB Hunt. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.82% higher. JB Hunt currently has a Zacks Rank of #3 (Hold). Digging into valuation, JB Hunt currently has a Forward P/E ratio of 18.62. For comparison, its industry has an average Forward P/E of 13.34, which means JB Hunt is trading at a premium to the group. We can also see that JBHT currently has a PEG ratio of 1.24. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Transportation - Truck industry currently had an average PEG ratio of 1.11 as of yesterday's close. The Transportation - Truck industry is part of the Transportation sector. This group has a Zacks Industry Rank of 55, putting it in the top 22% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow JBHT in the coming trading sessions, be sure to utilize Zacks.com. Just Released: The Biggest Tech IPOs of 2022 For a limited time, Zacks is revealing the most anticipated tech IPOs expected to launch this year. Concerns about Federal interest rates and inflation caused many private companies to stay on the bench- leading to companies with better brand recognition and higher growth rates getting into the game. With the strength of our economy and record amounts of cash flooding into IPOs, you don’t want to miss this opportunity. See the complete list today. >>See Zacks Hottest IPOs Now Click to get this free report J.B. Hunt Transport Services, Inc. (JBHT): Free Stock Analysis Report To read this article on … [Read more]( Actionable news --------------------------------------------------------------- [Stock Market Today - 5/27: Stocks Edge Higher On 'Fed Pause' Bets; Retail Earnings Mixed]( U.S. equity futures extended gains Friday, putting stocks on pace for their best weekly gain in two months, as investors bet that the Federal … [Read more]( Actionable news --------------------------------------------------------------- [Zacks Industry Outlook Highlights Delta Air Lines, Southwest Airlines and Alaska Air Group]( For Immediate Release Chicago, IL – May 27, 2022 – Today, Zacks Equity Research discusses Delta Air Lines DAL, Southwest Airlines LUV and Alaska Air … [Read more]( Actionable news --------------------------------------------------------------- [4 Reasons to Avoid Dividend-Paying Stocks]( Dividend stocks pay you to own them. But is there a catch? Sort of. Stocks that pay dividends have their downsides, or traits that may run contrary … [Read more]( Actionable news Follow us limex.me limex.me Warning: The links given in this email provide an automatic login to your account. For security purposes, do not share them with anyone. You received this letter because you created a Limex/WhoTrades/Try2BFunded/Score Priority/Just2Trade account. Do you want to unsubscribe from email notifications? [Edit your message settings](.